CGx Testing and Kickbacks Remain Key Enforcement Targets
In our latest roundup, schemes involving cancer genetic testing and kickbacks remain the most common, but there were some surprises.
Already a member? Log in here
January 2023 Labs in Court: Two Usual Cases, Two Unusual Ones
Key cases over the last month include a CGx testing kickback scheme, false billing, and violations of a non-compete clause and HIPAA.
Already a member? Log in here
The Promise of State-of-the-Art Sequencing Technologies for Cancer Screening
Circulating tumor DNA sequencing technologies are tackling the challenges of early cancer detection.
Already a member? Log in here
Recent Discovery Could Lead to a Better Lyme Disease Test
Researchers have identified 35 genes found in high expression in people with long-term Lyme disease, which could lead to earlier detection.
Already a member? Log in here
FY 2022 OIG Enforcement Rebounds—but Recovery Dollars Don’t Show It
The agency’s latest report to Congress shows that while enforcement activity is returning to pre-pandemic levels, recoveries are still down.
Already a member? Log in here